Navigation Links
AGU journal highlights -- Sept. 6, 2007
Date:9/10/2007

e. So, knowing the abundance of atmospheric hydrogen chloride is important to monitoring ozone depletion and ozone recovery following restrictions imposed by the Montreal Protocol, a treaty established in 1987 that sets timetables for phasing out chemicals that contribute to ozone destruction. Wallace and Livingston analyze data on atmospheric hydrogen chloride collected since 1971 by observers at the McMath-Pierce Solar Telescope on Arizona's Kitt Peak. Their data show the previously well established increase in hydrogen chloride abundance from 1971 to about 1993, thought to be due to unregulated use of chemicals that destroy ozone. These abundances plateau from about 1993 to about 1997. Since 1997, values have steadily decreased, the authors show. They attribute this decrease to the success of the Montreal Protocol.

Title:
The thirty-five year trend of hydrogen chloride amount above Kitt Peak, Arizona

Authors:
L. Wallace: National Optical Astronomy Observatories, Tucson, Arizona, U.S.A.;
W. C. Livingston: National Solar Observatory, Tucson, Arizona, U.S.A.

Source: Geophysical Research Letters (GRL) paper 10.1029/2007GL030123, 2007, http://dx.doi.org/10.1029/2007GL030123


4. Robotic probes improve global ocean analysis

Observations of the ocean are important to understanding global weather. Although satellites observe the open ocean, the Argo float network, a set of nearly 3000 oceanic robotic probes throughout the Earth's oceans that measure salinity and temperature at depths down to 2 kilometers (1.2 miles), has collected in situ data of the world's oceans since 2001. To analyze the importance of Argo in collecting accurate oceanic information, Balmaseda et al. use the European Centre for Medium-Range Weather Forecasts's operational ocean analysis system to replicate the past 5 years of global ocean behavior with and without Argo observations.
'/>"/>

Contact: Peter Weiss
pweiss@agu.org
202-777-7507
American Geophysical Union
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology news :

1. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
2. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
3. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
4. Open Access journals get impressive impact factors
5. Funding and bureaucracy, not access to journals, are chief obstacles to scientific productivity
6. New journal article urges use of animal serum-free media for growing live cells
7. Impressive new Impact Factors for BioMed Centrals open-access journals
8. Public Library of Science to launch new, open access journal on neglected tropical diseases
9. Are journal rankings distorting science?
10. New book highlights worlds borderless conservation areas
11. Learning to love bacteria: Stanford scientist highlights bugs benefits
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 2Princeton scientists find way to catalog all that goes wrong in a cancer cell 2Berkeley Lab researchers participate in Homeland Security study of subway airflow 2Lockheed Martin Expands Health IT Business with 24170 Million in New Health 26amp 3B Human Services Contract Awards 60095 1Lockheed Martin Expands Health IT Business with 24170 Million in New Health 26amp 3B Human Services Contract Awards 60095 2Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 1Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 2Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 3New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 1New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 2New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 3New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 4New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 5New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 6New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 7New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 8New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 9New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 10
Breaking Biology Technology:Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4
Other Biology Technology:Shire's New Product Portfolio Delivers Strong Quarterly Performance 2Shire's New Product Portfolio Delivers Strong Quarterly Performance 3Shire's New Product Portfolio Delivers Strong Quarterly Performance 4Shire's New Product Portfolio Delivers Strong Quarterly Performance 5Shire's New Product Portfolio Delivers Strong Quarterly Performance 6Shire's New Product Portfolio Delivers Strong Quarterly Performance 7Shire's New Product Portfolio Delivers Strong Quarterly Performance 8Shire's New Product Portfolio Delivers Strong Quarterly Performance 9Shire's New Product Portfolio Delivers Strong Quarterly Performance 10Shire's New Product Portfolio Delivers Strong Quarterly Performance 11Shire's New Product Portfolio Delivers Strong Quarterly Performance 12Shire's New Product Portfolio Delivers Strong Quarterly Performance 13Shire's New Product Portfolio Delivers Strong Quarterly Performance 14Shire's New Product Portfolio Delivers Strong Quarterly Performance 15Shire's New Product Portfolio Delivers Strong Quarterly Performance 16Shire's New Product Portfolio Delivers Strong Quarterly Performance 17Shire's New Product Portfolio Delivers Strong Quarterly Performance 18Shire's New Product Portfolio Delivers Strong Quarterly Performance 19Shire's New Product Portfolio Delivers Strong Quarterly Performance 20Shire's New Product Portfolio Delivers Strong Quarterly Performance 21Shire's New Product Portfolio Delivers Strong Quarterly Performance 22Shire's New Product Portfolio Delivers Strong Quarterly Performance 23Shire's New Product Portfolio Delivers Strong Quarterly Performance 24Shire's New Product Portfolio Delivers Strong Quarterly Performance 25Shire's New Product Portfolio Delivers Strong Quarterly Performance 26Shire's New Product Portfolio Delivers Strong Quarterly Performance 27Shire's New Product Portfolio Delivers Strong Quarterly Performance 28Shire's New Product Portfolio Delivers Strong Quarterly Performance 29Shire's New Product Portfolio Delivers Strong Quarterly Performance 30Shire's New Product Portfolio Delivers Strong Quarterly Performance 31Shire's New Product Portfolio Delivers Strong Quarterly Performance 32Shire's New Product Portfolio Delivers Strong Quarterly Performance 33Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 2Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 3Sinovac to Participate in Two Upcoming Investor Conferences 2